Tags

Type your tag names separated by a space and hit enter

Evaluation of the efficacy of Withania somnifera (Ashwagandha) root extract in patients with obsessive-compulsive disorder: A randomized double-blind placebo-controlled trial.
Complement Ther Med. 2016 Aug; 27:25-9.CT

Abstract

BACKGROUND

Obsessive-compulsive disorder (OCD) is a chronic psychiatric disorder that is causally linked to dysregulation of the serotonergic system. The aim of this study is to investigate the efficacy of Withania somnifera (W. somnifera) root extract as an adjunct therapy to standard OCD treatment.

METHODS

Thirty patients with a confirmed diagnosis of OCD according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria participated in this randomized double-blind placebo-controlled trial and were randomly assigned to the treatment group (W. somnifera extract, 120mg/day; n=15) or the placebo group (n=15). All patients were under treatment with Selective Serotonin Re-uptake Inhibitors (SSRIs), and were instructed to take 4 capsules of the extract or placebo per day, preferably after meals, for a period of six weeks. The Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) was used in order to assess the severity of OCD symptoms at baseline and at the end of the trial. Statistical analyses were performed using SPSS software and Y-BOCS values were presented as median and range (Min-Max).

RESULTS

Comparison of the change in Y-BOCS score during the course of the trial revealed a significantly greater effect of W. somnifera (26 (14-40) [pre-treatment] versus 14 (4-40) [post-treatment]; change: -8 (-23 to 0)) versus placebo (18 (11-33) [pre-treatment] versus 16 (10-31) [post-treatment]; change: -2 (-4 to 0)) (P<0.001). The extract was safe and no adverse event was reported during the trial.

CONCLUSION

W. somnifera extract may be beneficial as a safe and effective adjunct to SSRIs in the treatment of OCD.

Authors+Show Affiliations

Pharmaceutical Research Center, Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.Psychiatry and Behavioral Sciences Research Center, Ibn-e-Sina Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.Department of Pharmacogenosy, Pharmaceutical Research Center and School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.Pharmaceutical Research Center, Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.Gholampour Psychiatric Clinic, Mohtashami Avenue, Mashhad, Iran.Pharmaceutical Research Center, Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: mohamadpoorAH@mums.ac.ir.Neurogenic Inflammation Research Center, Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Metabolic Research Centre, School of Medicine and Pharmacology, Royal Perth Hospital, University of Western Australia, Perth, Australia.

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

27515872

Citation

Jahanbakhsh, Seyedeh Pardis, et al. "Evaluation of the Efficacy of Withania Somnifera (Ashwagandha) Root Extract in Patients With Obsessive-compulsive Disorder: a Randomized Double-blind Placebo-controlled Trial." Complementary Therapies in Medicine, vol. 27, 2016, pp. 25-9.
Jahanbakhsh SP, Manteghi AA, Emami SA, et al. Evaluation of the efficacy of Withania somnifera (Ashwagandha) root extract in patients with obsessive-compulsive disorder: A randomized double-blind placebo-controlled trial. Complement Ther Med. 2016;27:25-9.
Jahanbakhsh, S. P., Manteghi, A. A., Emami, S. A., Mahyari, S., Gholampour, B., Mohammadpour, A. H., & Sahebkar, A. (2016). Evaluation of the efficacy of Withania somnifera (Ashwagandha) root extract in patients with obsessive-compulsive disorder: A randomized double-blind placebo-controlled trial. Complementary Therapies in Medicine, 27, 25-9. https://doi.org/10.1016/j.ctim.2016.03.018
Jahanbakhsh SP, et al. Evaluation of the Efficacy of Withania Somnifera (Ashwagandha) Root Extract in Patients With Obsessive-compulsive Disorder: a Randomized Double-blind Placebo-controlled Trial. Complement Ther Med. 2016;27:25-9. PubMed PMID: 27515872.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation of the efficacy of Withania somnifera (Ashwagandha) root extract in patients with obsessive-compulsive disorder: A randomized double-blind placebo-controlled trial. AU - Jahanbakhsh,Seyedeh Pardis, AU - Manteghi,Ali Akhondpour, AU - Emami,Seyed Ahmad, AU - Mahyari,Saman, AU - Gholampour,Beheshteh, AU - Mohammadpour,Amir Hooshang, AU - Sahebkar,Amirhossein, Y1 - 2016/04/09/ PY - 2015/10/22/received PY - 2016/03/31/revised PY - 2016/03/31/accepted PY - 2016/8/13/entrez PY - 2016/8/16/pubmed PY - 2017/4/1/medline KW - Ashwagandha KW - Obsessive-compulsive disorder KW - Randomized controlled trial KW - Withania somnifera SP - 25 EP - 9 JF - Complementary therapies in medicine JO - Complement Ther Med VL - 27 N2 - BACKGROUND: Obsessive-compulsive disorder (OCD) is a chronic psychiatric disorder that is causally linked to dysregulation of the serotonergic system. The aim of this study is to investigate the efficacy of Withania somnifera (W. somnifera) root extract as an adjunct therapy to standard OCD treatment. METHODS: Thirty patients with a confirmed diagnosis of OCD according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria participated in this randomized double-blind placebo-controlled trial and were randomly assigned to the treatment group (W. somnifera extract, 120mg/day; n=15) or the placebo group (n=15). All patients were under treatment with Selective Serotonin Re-uptake Inhibitors (SSRIs), and were instructed to take 4 capsules of the extract or placebo per day, preferably after meals, for a period of six weeks. The Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) was used in order to assess the severity of OCD symptoms at baseline and at the end of the trial. Statistical analyses were performed using SPSS software and Y-BOCS values were presented as median and range (Min-Max). RESULTS: Comparison of the change in Y-BOCS score during the course of the trial revealed a significantly greater effect of W. somnifera (26 (14-40) [pre-treatment] versus 14 (4-40) [post-treatment]; change: -8 (-23 to 0)) versus placebo (18 (11-33) [pre-treatment] versus 16 (10-31) [post-treatment]; change: -2 (-4 to 0)) (P<0.001). The extract was safe and no adverse event was reported during the trial. CONCLUSION: W. somnifera extract may be beneficial as a safe and effective adjunct to SSRIs in the treatment of OCD. SN - 1873-6963 UR - https://www.unboundmedicine.com/medline/citation/27515872/Evaluation_of_the_efficacy_of_Withania_somnifera__Ashwagandha__root_extract_in_patients_with_obsessive_compulsive_disorder:_A_randomized_double_blind_placebo_controlled_trial_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0965-2299(16)30050-4 DB - PRIME DP - Unbound Medicine ER -